Epcoritamab, a cancer drug co-developed by (NYSE: ABBV) and Genmab (NASDAQ: GMAB), was recently given the green light by the Food and Drug Administration to be used as a treatment for adults with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL).

What could this news mean for patients diagnosed with R/R DLBCL? And how much of a lift in sales could it provide to the pharmaceutical companies? Let's drill down into the efficacy of epcoritamab (marketed as Epkinly) and this specific lymphoma market to find out.

Of all blood cancers, lymphoma is the most common. The disease impacts lymphocytes, which are a type of white blood cell that protects the body from bacteria and viruses. Lymphoma generally happens when lymphocytes mutate, which leads to a cell replicating more rapidly than a normal lymphocyte.

Continue reading

Source Fool.com